Navigation Links
ArterX™ Clinical Trial Results Announced at Veith Meeting
Date:11/18/2010

MOUNTAIN VIEW, Calif., Nov. 18, 2010 /PRNewswire/ -- US clinical trial results for Tenaxis' investigational vascular surgical sealant, ArterX, were presented today at the Veith Meeting in New York.  William M. Stone, MD of the Mayo Clinic, Scottsdale AZ reported a more than 20% margin of improvement for ArterX Surgical Sealant in the sealing of vascular suture lines compared with a control group featuring a commercially available gelatin foam/thrombin combination.

In a presentation titled "A Novel More Effective Glue-Sealant (ArterX) for Hemostasis at Vascular Suture Lines and Other Sites," Dr. Stone reported that ArterX Surgical Sealant achieved immediate hemostasis more than 60% of the time in a 217 patient clinical trial conducted at 11 different hospitals in the US.

President and CEO, David Smith, commented, "We are delighted with the preliminary results of our US clinical trial.  We were also able to show a statistically significant reduction in operating time of 36 minutes in the ArterX group, and ArterX patients were discharged from hospital after 4.1 days, an improvement of 1.3 days over the control group. If approved, we believe that ArterX Surgical Sealant will yield economic benefits for surgeons and hospitals that adopt it."

ArterX Surgical Sealant is currently under review by the FDA and is not available for sale in the USA.

ArterX is CE Marked in the European Union

About Tenaxis Medical, Inc.

Incorporated in 2004 and located in Mountain View, CA, Tenaxis Medical, Inc. is a privately held Company. It develops novel, high performance sealants for use in vascular and general surgery. In addition to the ArterX Surgical Sealant, the company is developing a second high performance sealant for use throughout the gastrointestinal tract, and an anti-adhesion agent that can be delivered  laparoscopically to help prevent or reduce pelvic and abdominal adhesions.Contact: Ronald Dieck+1-650-691-9016, ext.
'/>"/>

SOURCE Tenaxis Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
2. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Clinical Experts Describe Radiosurgical Advances for Brain, Breast, and Spinal Cancers
5. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
6. PAREXEL Wins Clinical Research Team of the Year Scrip Award
7. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
8. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
9. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
10. Frost & Sullivan Recognizes Merge Healthcares Clinical Imaging Management Solution as Game Changing Technology
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) ... the post-approval study of its NeuRx DPS® System ... meet the FDA enrollment requirement was implanted over ... The NeuRx DPS®, which is the only medical ... patients, is a humanitarian device that obtained approval ...
(Date:9/30/2014)... Sept. 30, 2014  eHealth, electronic access of ... access of this information, has become a major ... that has not translated into user-friendly, effective products. ... - http://photos.prnewswire.com/prnh/20140929/149123 For ... years developing MWD® Health Manager iEHR, a multilingual ...
(Date:9/30/2014)... Sept. 30, 2014 It is evident from the ... is not performing upto expectations due to the lack of ... with the intake of omega-3 fatty acids. Among omega-3 ingredient ... fish oil, attributed to the large vegetarian population in ... polyunsaturated fatty acid (PUFAs) ingredients is in growth stage of ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... The 2009 Frost & Sullivan European Medical ... the radiology applications market is conferred on Viatronix ... the diagnostic imaging space. , (Logo: ... Viatronix has shown dedication to both developing and ...
... PAC, a leading global provider of advanced analytical instruments ... of the ANTEK MultiTek(TM) testing system for the fast, ... and halides. Industries include BioFuels, Chemicals, Food & Beverage, ... , "MultiTek(TM) is the only instrument on the ...
Cached Medicine Technology:Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 2Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 3Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 4New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2
(Date:9/30/2014)... 2014 issue of The FASEB Journal ... a simple blood test. This test, called the "lymphocyte genome ... than ever before, but it may eliminate the need for ... likely to develop cancer in the future. , "The ... peoples, lives," said Diana Anderson, a researcher involved in the ...
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. 29, 2014 ... -- artificial valves, hip replacements, surgical mesh and the like ... after their approval by the U.S. Food and Drug Administration, ... prominent nonprofit groups and published online Sept. 29 in ... medical device testing on lax oversight by the FDA. ...
(Date:9/30/2014)... 30, 2014 Edward D. Buckingham, M.D., ... has been approved to be a director of a ... Reconstructive Surgery (AAFPRS) fellowship program. The announcement came last ... Florida. , The Educational and Research Foundation for the ... It represents the finest postgraduate program in the world ...
(Date:9/30/2014)... NC (PRWEB) September 30, 2014 ... and caring individuals, National Children’s Oral Health ... $150,000 in grants to non-profit clinical partners. ... Affiliate Network and deliver comprehensive educational, preventive ... , Recipients include:,     Just ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Herceptin is ... cancer called HER2-positive and should remain the standard of ... findings from a long-term clinical trial. HER2-positive breast ... of breast cancer, according to the Mayo Clinic. ... countries received either Herceptin (trastuzumab) or Tykerb (lapatinib) in ...
Breaking Medicine News(10 mins):Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3
... from UCSF examining HIV among men who have sex with men ... that a third of gay-identified men are infected with HIV. ... HIV and the community of men who have sex with men ... reserved for black South Africans during apartheid. The researchers ...
... BANNOCKBURN, Ill., Aug. 31 Omron Healthcare has announced a ... The achievement is part of a journey that began 36 years ... , , What has followed since 1973? The ... around the world. From PC compatible units which allow you to ...
... , , , ... Ingelheim today announced that results from the RE-LY(R) (Randomized Evaluation of ... atrial fibrillation (AF) outcomes trial ever conducted(1) (18,113 patients in 44 ... European Society of Cardiology Congress and published online in the ...
... ... care and non-medical caregiver services in Northern California and Utah, has been approved for ... its Haven Healthcare office in Layton, Utah , ... Walnut Creek, CA (PRWEB) August 29, 2009 -- Professional ...
... ... show and discusses how to integrate the color blue for to calm the body and ... and and professional communications. , ... (Vocus) August 29, 2009 -- ColorAlchemy is featured on HeartandHome radio show (heartandhomehealing.com/upcoming_shows.htm) and discusses ...
... were affected, study found , FRIDAY, Aug. 28 (HealthDay ... may determine their odds for progressing to AIDS-linked dementia, ... are a common hallmark of HIV infection. But during ... Sacktor noted that people in areas where HIV subtypes ...
Cached Medicine News:Health News:High HIV infection rate among Soweto Township gays 2Health News:And the Beat Goes on 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 4Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 5Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 6Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 7Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 8Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 9Health News:Professional Healthcare Is Approved for Medicare Licenses at Additional Offices in California and Utah 2Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 2Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 3Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 4
Remote Controlled, Easy to Use,Vision Tester Designed for Screening Children Ages 3 and Older.,Excellent for Pediatric and School Markets....
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Adult: Letter Acuity, Astigmatic Clock, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Medicine Products: